KO
KOREA PHARMA Co., Ltd.
032300 | KO
Overview
Corporate Details
- ISIN(s):
- KR7032300006
- LEI:
- Country:
- South Korea
- Address:
- 경기도 화성시 향남읍 제약공단3길 87, 화성시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.2 MB | ||
| 2025-08-07 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 127.8 KB | ||
| 2025-05-14 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-05-14 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 137.1 KB | ||
| 2025-04-01 00:00 |
M&A Activity
합병등종료보고서(자산양수도)
|
Korean | 14.9 KB | ||
| 2025-03-28 00:00 |
AGM Information
정기주주총회결과
|
Korean | 30.2 KB | ||
| 2025-03-28 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 11.5 KB | ||
| 2025-03-20 00:00 |
Audit Report / Information
사업보고서 (2024.12)
|
Korean | 572.5 KB | ||
| 2025-03-14 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 18.5 KB | ||
| 2025-03-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 18.9 KB | ||
| 2025-03-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 103.6 KB | ||
| 2025-03-12 00:00 |
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
|
Korean | 4.3 KB | ||
| 2025-03-07 00:00 |
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 10.8 KB | ||
| 2025-03-07 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정
|
Korean | 8.5 KB | ||
| 2025-02-07 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 124.9 KB |
Automate Your Workflow. Get a real-time feed of all KOREA PHARMA Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for KOREA PHARMA Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for KOREA PHARMA Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
United States of America
ACXP
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
United States of America
ADAP
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
South Korea
179530
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
United States of America
ADCT
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland
ADXN
Switzerland
ADXN
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
United States of America
ADIL
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
United States of America
ACET
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
United States of America
ANL
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
United States of America
ADMA
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM
United States of America
ADVM